Optics
← Today's headlines

3 sources checked · Left, Center, and Right included · 3h ago

Different Spin

FDA rejects cancer drug invented in China in blow to Beijing’s biotech sector

New York Times - Business and Investor's Business Daily describe the same event in different terms.

1 Left1 Center1 Right
Same story. Different framing. Left, center, and right outlets are covering the same event. Here’s how each side worded it.

DIFFERENT SPIN

HOW EACH SIDE WORDED IT

Left-leaningCenter-leftF.D.A. Rejects Closely Watched Lung Cancer Drug From ChinaNew York Times - BusinessMostly Factual
Right-leaningCenter-rightFDA Doesn't Approve Summit's China-Developed Lung Cancer DrugInvestor's Business DailyMostly Factual
Center baseline · Financial Times - CompaniesHighFDA rejects cancer drug invented in China in blow to Beijing’s biotech sector

As of November 15, 2026 at 8:33 PM, this is how Optics News reads the wording differences in this story.

What happened Summit’s Ivonescimab was seen as a test case for whether the country’s medicine could pass scrutiny in the US.
The headline split The left frames it as "F.D.A. Rejects Closely Watched Lung Cancer Drug From China". The right frames it as "FDA Doesn't Approve Summit's China-Developed Lung Cancer Drug".
Match confidence Medium confidence. 3 sources across 3 bias buckets. Useful framing signal — check the source list before sharing.
Same-event confidenceMedium

3 sources across 3 bias buckets agree on the event.

Framing confidenceModerate

68/99 — meaningful wording shift across the spectrum.

WHAT EACH SIDE EMPHASIZED

Left / center-leftF.D.A. Rejects Closely Watched Lung Cancer Drug From China

New York Times - Business · Center-left · News report

CenterFDA rejects cancer drug invented in China in blow to Beijing’s biotech sector

Financial Times - Companies · Center · News report

Right / center-rightFDA Doesn't Approve Summit's China-Developed Lung Cancer Drug

Investor's Business Daily · Center-right · News report

SEE THE HEADLINES

CenterHigh
Financial Times - CompaniesNews report · Nov 15, 5:07 PM

FDA rejects cancer drug invented in China in blow to Beijing’s biotech sector

Summit’s Ivonescimab was seen as a test case for whether the country’s medicine could pass scrutiny in the US

Open source
Center-rightMostly Factual
Investor's Business DailyNews report · Nov 15, 7:34 PM

FDA Doesn't Approve Summit's China-Developed Lung Cancer Drug

The FDA said Summit Therapeutics' lung cancer drug ivonescimab, developed in China, failed to show a statistically significant survival benefit.

Open source
Center-leftMostly Factual
New York Times - BusinessNews report · Nov 15, 8:33 PM

F.D.A. Rejects Closely Watched Lung Cancer Drug From China

The treatment, called ivonescimab, has become a symbol of China’s rise in drug development.

Open source
Details68/99 Wording Gap · Medium confidence · 3 sources
68/99 Wording GapMedium confidence3 sources · 3 bias bucketsLive match · 3 sources · 3 buckets · comparable news formatFormats: News report

SOURCE MAP CHANGES

Nov 15, 5:07 PM: Financial Times - Companies joined the source map.

Nov 15, 7:34 PM: Investor's Business Daily joined the source map.

Nov 15, 8:33 PM: New York Times - Business joined the source map.

Now: Wording Gap is 68/99 and story health is live match · 3 sources · 3 buckets · comparable news format.